Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 1/20 | 0.61 |
| ▸ | KDR | P35968 | 1/20 | 0.61 |
| ▸ | SGK1 | O00141 | 15/20 | 0.57 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.43 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.43 |
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2820453 | 0.92 | KIT (0.50) | KITKDRSGK1NPY5RALDH1A1 | |
| SCHEMBL2816673 | 0.90 | KIT (0.52) | KITKDRSGK1ALDH1A1HPGD | |
| SCHEMBL2819079 | 0.89 | KIT (0.51) | KITKDRSGK1 | |
| SCHEMBL2819281 | 0.88 | SGK1 (0.49) | KITKDRSGK1 | |
| SCHEMBL2816080 | 0.86 | SGK1 (0.51) | KITKDRSGK1ALDH1A1HPGD | |
| SCHEMBL2818267 | 0.86 | ALDH1A1 (0.48) | KITKDRSGK1ALDH1A1 | |
| SCHEMBL2816535 | 0.83 | SGK1 (0.54) | SGK1 | |
| SCHEMBL2819284 | 0.82 | KDR (0.58) | KITKDR | |
| SCHEMBL2816184 | 0.82 | KIT (0.59) | KITKDRSGK1KEAP1NPY5R | |
| SCHEMBL2821071 | 0.81 | KDR (0.54) | KITKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842809-B2 | Pyrazolopyridines and salts thereof, a pharmaceutical composition comprising said compounds, a method of preparing same and use of same | BAYER SCHERING PHARMA AG (DE) | 2010-11-30 | — | — | US | claimed |
| EP-1841767-A1 | PYRAZOLOPYRIDINES, THEIR PREPARATION AND THEIR MEDICAL USE | Bayer Schering Pharma AG (DE) | 2007-10-10 | — | — | EP | claimed |
| US-20060252754-A1 | Pyrazolopyridines and salts thereof, a pharmaceutical composition comprising said compounds, a method of preparing same and use of same | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2006-11-09 | — | — | US | claimed |
| WO-2006077168-A1 | PYRAZOLOPYRIDINES, THEIR PREPARATION AND THEIR MEDICAL USE | BAYER SCHERING PHARMA AG. (DE) | 2006-07-27 | — | — | WO | claimed |
| US-7842809-B2 | Pyrazolopyridines and salts thereof, a pharmaceutical composition comprising said compounds, a method of preparing same and use of same | BAYER SCHERING PHARMA AG (DE) | 2010-11-30 | — | — | US | disclosed |
| US-7842809-B2 | Pyrazolopyridines and salts thereof, a pharmaceutical composition comprising said compounds, a method of preparing same and use of same | BAYER SCHERING PHARMA AG (DE) | 2010-11-30 | — | — | US | disclosed |
| US-7842809-B2 | Pyrazolopyridines and salts thereof, a pharmaceutical composition comprising said compounds, a method of preparing same and use of same | BAYER SCHERING PHARMA AG (DE) | 2010-11-30 | — | — | US | disclosed |
| EP-1841767-A1 | PYRAZOLOPYRIDINES, THEIR PREPARATION AND THEIR MEDICAL USE | Bayer Schering Pharma AG (DE) | 2007-10-10 | — | — | EP | disclosed |
| US-20060252754-A1 | Pyrazolopyridines and salts thereof, a pharmaceutical composition comprising said compounds, a method of preparing same and use of same | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2006-11-09 | — | — | US | disclosed |
| WO-2006077168-A1 | PYRAZOLOPYRIDINES, THEIR PREPARATION AND THEIR MEDICAL USE | BAYER SCHERING PHARMA AG. (DE) | 2006-07-27 | — | — | WO | disclosed |
| EP-1683796-A1 | Pyrazolopyridines, their preparation and their medical use | Schering Aktiengesellschaft (DE) | 2006-07-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252754-A1 | Pyrazolopyridines and salts thereof, a pharmaceutical composition comprising said compounds, a method of preparing same and use of same | TEK, TIE1, KDR | KIT 8/4885KDR 3/4885SGK1 2534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.